+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Digital Solutions for Biomarkers Market by Content, Purpose, Type of Biomarker, Therapeutic Area, Business Model, and by Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • ID: 5306198
  • Report
  • January 2021
  • Region: Global
  • 272 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 5AM Ventures
  • Byteflies
  • FitBit
  • Karate Health
  • Novatio Ventures
  • Silicon Valley Bank

Overview

From periodically monitoring disease progression in patients to developing customized therapies based on genetic predisposition, biomarkers (which are specific indicators of biological events) have become an indispensable aspect of contemporary healthcare solutions/practices. Ongoing digitization efforts in the healthcare industry have led to the development of a number of digital solutions, which are capable of generating, collecting, and tracking medical data. From this data, details of anatomical, physiological, and molecular events, and even behavior-related patterns in humans, or digital biomarkers, have been acknowledged as viable inputs to explain, influence and/or predict health-related outcomes. Digital biomarkers are analyzed in silico, using advanced analytical algorithms and artificial intelligence (AI) enabled tools, and therefore, can be used to rapidly generate actionable insights and identify previously undetected biological events (obscured by the shortcomings of manual processes). In this context, regulatory bodies across the world have actually begun evaluating software as a medical device. Fundamentally, digital biomarkers are identified/measured using sensors and algorithms across the plethora of available connected medical devices and other health-focused software solutions. Moreover, the fact that the procurement/analysis of digital biomarkers are not limited to the physical confines of the clinical environment, presents new opportunities to revolutionize disease diagnosis, patient monitoring and clinical trial conduct. When combined with specific phenotypic signatures, digital biomarkers have demonstrated the potential to be used to generate insights related to esoteric medical fields, such as psychiatry and neurology. In fact, experts believe that future diagnostic/treatment protocols for certain mental health indications are likely to be underpinned by digital biomarkers, similar to how the management of diabetes and hypertension are underpinned by biochemical biomarkers.

In the current pandemic scenario, medical professionals are trying to identify digital biomarkers that can facilitate the successful screening/diagnosis of COVID-19 patients, remotely. For instance, the National Institutes of Health (NIH) has tasked physIQ with developing and validating an algorithm, which can use existing wearable biosensor-derived analytics (generated by the company’s pinpointIQ™ cloud platform) to discover a novel digital biomarker for COVID-19 associated decompensation. In this regard, it is worth noting that the development of tools to capture digital biomarkers and analyze them, requires multidisciplinary (including computer science and engineering, as well as neology and medicine) expertise. Currently, several successful start-ups claim to be involved in designing and developing the necessary software/hardware solutions for the abovementioned purposes. Most of these companies have also received significant capital investments to support their respective product development initiatives. One of the primary challenges encountered by innovators in this market is related to regulatory review. Digital biomarkers are subjected to the same level of regulatory scrutiny as their traditional counterparts. Moreover, there is an evident need for a systematic approach to assess the quality and utility of digitized renderings of biological events, in order to gauge their safety and efficacy in informing health-related decision making. Despite existing challenges, this niche, but emerging domain, is expected to evolve complementary to digital therapeutics, with pioneers in the field poised to benefit from the first-to-market advantage. Given the recent rise in partnership activity in this field, and the growing demand for remote diagnostic and therapeutic solutions (mostly influenced by the pandemic), we believe that the digital biomarkers market is likely to grow at a healthy pace over the next decade.

Scope of the Report

The “Digital Solutions for Biomarkers Market by Content of Solution (Standalone Software Solutions and Combination Offerings), Purpose of Solution (Diagnosis, Early Screening, Monitoring, and Predictive Insights), Type of Biomarker (Cognitive, Idiosyncratic, Physiological, Vocal, and Other Biomarkers), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Disorders, Mental Health Problems, Neurological Disorders, Respiratory Disorders, Substance Use Disorders, and Other Disorders), Business Model (B2B and B2C), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030 ” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of digital solutions for biomarkers (either commercialized or under development) in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. 

Amongst other elements, the report includes:

  • An overview of the current market landscape of digital solutions for biomarkers, including information on current status (approved, marketed, USFDA submission, research and development, proof-of-concept, and discovery), content of solution (combination offering of  software application/gaming solution + AI support or device or personal coach, and standalone software/gaming solution ), purpose of solution (diagnosis, early screening, monitoring and predictive insights), type of biomarker (cognitive, idiosyncratic, molecular, neurophysiological, physiological, respiratory, vocal, and others ), target indication(s), therapeutic area(s), target population, and prescription requirement. In addition, it highlights the companies engaged in developing digital solutions for biomarkers, along with information on their year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.
  • An in depth analysis of the contemporary market trends, presented using five schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of digital solutions for biomarkers, based on various parameters (such as product portfolio strength, type of biomarker and company size), [B] a grid representation illustrating the distribution of digital solutions for biomarkers based on their current status, content of solution and target therapeutic area, [C] an insightful tree map representation of digital solutions for biomarkers based on their therapeutic area and company size, [D] a world map representation highlighting the regional distribution of developer companies, and [E] a comparative grid representation to highlight the current and likely future market landscape based on status of development, type of biomarker and therapeutic area.  
  • Elaborate profiles of prominent players that are either currently engaged in developing or have developed digital solutions for biomarkers. Each company profile features a brief overview of the company (with information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective product portfolios, recent developments and an informed future outlook.
  • A detailed product competitiveness analysis of digital solutions for biomarkers taking into consideration several relevant parameters, such as current status, content of solution, purpose of solution, therapeutic area, and prescription requirement.
  • An analysis of the recent global events (summits/forums/conferences/annual meetings) that were organized for stakeholders engaged in this domain, highlighting the evolution of discussion topics related to digital solutions for biomarkers. The chapter also includes details on type of event, regional distribution, emerging agendas, popular organizers, and most active industry and non-industry players.
  • An elaborate analysis of the investments, including seed financing, venture capital financing, debt financing, grants/awards, made at various stages of development in companies that are engaged in this field, during the period 2012-2020 (till September). 
  • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2014 and 2020 (till September), covering marketing and distribution agreements, mergers/acquisitions, pilot programs, product/technology integration agreements, product/technology licensing agreements, product development agreements, product development and commercialization agreements, product evaluation agreements, and research and development agreements.
  • An analysis of the various digital solutions for biomarkers focused initiatives carried out by big pharma players (out of top 25 established pharmaceutical players), featuring [A] an analysis highlighting information on clinical research activity, funding, partnership activity, research publications, and participation in conferences, and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the overall digital solutions for biomarkers market, along with information on the key initiatives undertaken by big pharma players to overcome the challenges faced due to the pandemic.

One of the key objectives of the report was to estimate the existing market size and future opportunity for digital solutions for biomarkers developers over the next decade. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity within digital solutions for biomarkers market across [A] content of solution (combination offering of software application + device or AI, and standalone software applications), [B] purpose of solution (diagnosis, early screening, monitoring and predictive insights), [C] type of biomarker (cognitive, idiosyncratic, physiological, vocal, and other biomarkers), [D] therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), [E] business model (B2B (healthcare providers, payers, employers and pharmaceutical companies) and B2C (patients and caregivers)), and [F] key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. 

The report features detailed transcripts of interviews held with the following industry stakeholders: 

  • Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
  • Michael Seggev (Chief Commercial Officer, Vocalis Health)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in digital solutions for biomarkers?
  • Which popular therapeutic areas are being targeted by digital solutions for biomarkers?
  • Which players are actively involved in organizing/participating in global events conducted within this domain?
  • What is the trend for capital investments in the digital solutions for biomarkers market?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • What type of strategies are being adopted by big pharma players engaged in this domain?
  • How is the recent COVID-19 pandemic likely to impact the overall digital solutions for biomarkers market?
  • What are the opportunities available for digital solutions for biomarkers in emerging markets?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to digital solutions for biomarkers market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 5AM Ventures
  • Byteflies
  • FitBit
  • Karate Health
  • Novatio Ventures
  • Silicon Valley Bank

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1 Chapter Overview
3.2. Overview of Digital Biomarkers 
3.2.1 Classification of Digital Biomarkers
3.2.2 Key Advantages and Limitations
3.3. Digital Biomarker-related Product Development and Commercialization Path
3.3.1. Product Discovery and Development
3.3.2. Validation and Regulatory Submissions
3.3.3. Distribution and Marketing 
3.4. Prevalent Trends Related to Digital Biomarkers
3.4.1. Emerging Focus Areas
3.4.2. Key Historical Trends
3.4.3. Geographical Activity

4 . MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Solutions for Biomarkers: Overall Market Landscape
4.2.1. Analysis by Current Status
4.2.2. Analysis by Content of Solution
4.2.3. Analysis by Purpose of Solution
4.2.4. Analysis by Type of Biomarker
4.2.5. Analysis by Target Indication(s)
4.2.6. Analysis by Therapeutic Area 
4.2.7. Analysis by Target Population
4.2.8. Analysis by Prescription Requirement
4.3. Digital Solutions for Biomarkers: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Business Model Used
4.3.4 Analysis by Location of Headquarters
4.4. Leading Developers: Analysis by Number of Digital Solutions for Biomarker 
4.5. Digital Solutions for Biomarkers: Information on Additional Players

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. 4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size
5.3. Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
5.4. Treemap Representation: Analysis by Therapeutic Area and Company Size
5.5. World Map Representation: Analysis by Location of Headquarters
5.6. Current and Future Market Landscape Trends Analysis

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Acculi Labs
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Canary Health Technologies
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Empatica
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 IXICO
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook 
6.6. Kinsa
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook 
6.7. Progentec Diagnostics
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook 
6.8. Vocalis Health
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook

7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters and Methodology
7.3. Product Competitiveness Analysis
7.3.1. Product Competitiveness Analysis: Idiosyncratic Biomarkers
7.3.2. Product Competitiveness Analysis: Physiological Biomarkers
7.3.3. Product Competitiveness Analysis: Vocal Biomarkers
7.3.4. Product Competitiveness Analysis: Other Biomarkers

8. GLOBAL EVENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Global Events Related to Digital Biomarkers 
8.3.1. Analysis by Year of Occurrence
8.3.2. Analysis by Event Platform
8.3.3. Analysis by Geography
8.3.4. Analysis by Type of Event
8.3.5. Evolutionary Trend in Key Agenda/Event Agenda
8.3.6. Most Active Event Organizers
8.3.7. Most Active Players in Terms of Event Participation
8.3.8. Analysis by Seniority Level of Participants

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Digital Solutions for Biomarkers: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Biomarker
9.3.5. Analysis by Therapeutic Area
9.3.6. Analysis by Geography 
9.3.7. Most Active Players: Analysis by Number of Instances
9.3.8. Most Active Players: Analysis by Amount Invested
9.3.9. Most Active Investors: Analysis by Number of Instances
9.4 Concluding Remarks

10. PARTNERSHIPS AND COLLABORATIONS 
10.1. Chapter Overview
10.2. Partnership Models
10.3. Digital Solutions for Biomarkers: Recent Partnerships and Collaborations 
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.2.1. Analysis by Type of Partnership and Year of Partnership
10.3.2.2. Analysis by Type of Partnership and Company Size
10.3.3. Analysis by Type of Partner
10.3.3.1. Analysis by Type of Partner and Year of Partnership
10.3.3.2. Analysis by Type of Partner and Type of Partnership
10.3.3.3. Analysis by Type of Partner and Company Size
10.3.4. Analysis by Type of Biomarker
10.3.4.1. Analysis by Type of Biomarker and Year of Partnership
10.3.4.2. Analysis by Type of Biomarker and Type of Partnership
10.3.5. Analysis by Therapeutic Area
10.3.5.1. Analysis by Therapeutic Area and Year of Partnership
10.3.5.2 Analysis by Therapeutic Area and Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Regional Analysis
10.3.8. Intercontinental and Intracontinental Agreements

11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Digital Biomarker-related Initiatives of Big Pharma Players
11.3.1. Clinical Research Activity
11.3.2. Partnership Activity
11.3.3. Funding and Investments
11.3.4. Participation in Global Events
11.3.5. Research Publications
11.4. Benchmark Analysis of Big Pharmaceutical Players
11.4.1. Spider Web Analysis: Company A
11.4.2. Spider Web Analysis: Company B
11.4.3. Spider Web Analysis: Company C
11.4.4. Spider Web Analysis: Company D
11.4.5. Spider Web Analysis: Company E
11.4.6. Spider Web Analysis: Company F
11.4.8. Spider Web Analysis: Company G
11.4.8. Spider Web Analysis: Company H
11.4.9. Spider Web Analysis: Company I
11.4.10. Spider Web Analysis: Company J
11.4.11. Spider Web Analysis: Company K
11.4.12. Spider Web Analysis: Company L
11.4.13. Spider Web Analysis: Company M

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Digital Solutions for Biomarkers Market, 2021-2030
12.4. Digital Solutions for Biomarkers Market: Distribution by Content of Solution
12.4.1. Digital Solutions for Biomarkers Market for Standalone Software Applications, 2021-2030
12.4.2. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support), 2021-2030
12.4.3. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + Device), 2021-2030
12.4.4. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support + Device), 2021-2030
12.4.5. Digital Solutions for Biomarkers Market for Other Content of Solutions, 2021-2030
12.5. Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution
12.5.1. Digital Solutions for Biomarkers Market for Diagnosis, 2021-2030
12.5.2. Digital Solutions for Biomarkers Market for Early Screening, 2021-2030
12.5.3. Digital Solutions for Biomarkers Market for Monitoring, 2021-2030
12.5.4. Digital Solutions for Biomarkers Market for Predictive Insights, 2021-2030
12.6. Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker
12.6.1. Digital Solutions for Cognitive Biomarkers Market, 2021-2030
12.6.2. Digital Solutions for Idiosyncratic Biomarkers Market, 2021-2030
12.6.3. Digital Solutions for Physiological Biomarkers Market, 2021-2030
12.6.4. Digital Solutions for Vocal Biomarkers Market, 2021-2030
12.6.5. Digital Solutions for Other Biomarkers Market, 2021-2030
12.7. Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area
12.7.1. Digital Solutions for Biomarkers Market for Autoimmune Disorders, 2021-2030
12.7.2. Digital Solutions for Biomarkers Market for Cardiovascular Disorders, 2021-2030
12.7.3. Digital Solutions for Biomarkers Market for Infectious Disorders, 2021-2030
12.7.4. Digital Solutions for Biomarkers Market for Mental Health Problems, 2021-2030
12.7.5. Digital Solutions for Biomarkers Market for Neurological Disorders, 2021-2030
12.7.6. Digital Solutions for Biomarkers Market for Respiratory Disorders, 2021-2030
12.7.7. Digital Solutions for Biomarkers Market for Substance Use Disorders, 2021-2030
12.7.8. Digital Solutions for Biomarkers Market for Other Disorders, 2021-2030
12.8. Digital Solutions for Biomarkers Market: Distribution by Business Model 
12.8.1. Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2021-2030
12.8.2. Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), 2021-2030
12.9. Digital Solutions for Biomarkers Market: Distribution by Key Geographical Regions
12.9.1. Digital Solutions for Biomarkers Market in North America, 2021-2030
12.9.2. Digital Solutions for Biomarkers Market in Europe, 2021-2030
12.9.3. Digital Solutions for Biomarkers Market in Asia-Pacific, 2021-2030
12.9.4. Digital Solutions for Biomarkers Market in Middle East and North Africa (MENA), 2021-2030
12.9.5. Digital Solutions for Biomarkers Market in Rest of the World, 2021-2030
12.10. Concluding Remarks

13. IMPACT OF COVID-19 PANDEMIC ON DIGITAL SOLUTIONS FOR BIOMARKERS MARKET
13.1. Chapter Overview
13.2. Impact of COVID-19 Pandemic on Digital Solutions for Biomarkers Market
13.2.1. Impact on Future Market Opportunity for Digital Solutions for Biomarkers  
13.3. Current Opinions and Key Initiatives of Key Players
13.4. Recuperative Strategies for Developer Businesses
13.4.1. Strategies for Implementation in the Short/Mid Term
13.4.2. Strategies for Implementation in the Long Term

14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Tilak Healthcare
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer
15.3. Vocalis Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Michael Seggev, Chief Commercial Officer

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

Note: Product cover images may vary from those shown
  • 5AM Ventures
  • AAF Management
  • Accel Diagnostics
  • Accelmed Growth Partners
  • Acculi Labs
  • ActiGraph
  • AiCure
  • Air Force Research Laboratory
  • Akili Interactive
  • A-klinikka Oy
  • Albion Capital
  • Alector
  • AliveCor
  • Alpana Ventures
  • Altoida
  • Alumni Ventures Group
  • Americans superenkeleiltä
  • Amgen
  • Amgen Ventures
  • aMoon
  • Apple
  • Applied Morphomics
  • Arboretum Ventures
  • Asahi Kasei
  • Baillie Gifford
  • Baird Capital
  • Battery Ventures
  • Bayer
  • Ben Franklin Technology Partners of Northeastern Pennsylvania
  • BioBeats
  • Biogen
  • Biomatics Capital
  • Biomedical Advanced Research and Development Authority
  • Bio-Rad Laboratories
  • Biosensics
  • BizTech
  • BlackThorn Therapeutics
  • Blue Water Life Science Fund
  • Bridge Builders Collaborative
  • Bristol-Myers Squibb
  • Brooklands Capital Strategies
  • Burns & Stowers Investments
  • byFounders
  • Byteflies
  • CAIRE
  • Canary Health Technologies
  • Canepa Advanced Healthcare Fund
  • Capital Partners
  • Cardiac Insight
  • CareFirst BlueCross BlueShield
  • Carmen Innovations
  • Castor Ventures
  • Cerora
  • CincyTech
  • CLSA
  • Clue
  • Cogito
  • Cognetivity Neurosciences
  • Cogstate
  • Cohero Health
  • Connetic Ventures
  • Contiguity
  • CoreSyte
  • Corti
  • Creative Destruction Lab
  • Crush The Curve Idaho
  • Dale Ventures
  • DG Daiwa Ventures
  • DigiBio
  • Digital Health Ecosystem Wales
  • Eccrine Systems
  • EDBI
  • Eisai
  • EIT Health
  • Elektra Labs
  • Eli Lilly
  • Empatica
  • Endeavor Catalyst
  • EU Executive Agency for SMEs (EASME)
  • Eyelogics
  • Fearless Ventures
  • FeetMe
  • Tesi
  • First Star Ventures
  • FirstMark Capital
  • FitBit
  • Flying Health
  • Forerunner Ventures
  • Founder Collective
  • FYRFLY Venture Partners
  • GE Healthcare
  • GE Ventures
  • GlaxoSmithKline
  • Goldman Sachs Growth Equity (GS Growth)
  • Gradient Ventures
  • Grey Sky Venture Partners
  • GSR Ventures
  • Happify Health
  • Healios
  • Healthbox
  • Healthymize
  • Hearst Ventures
  • Heartcore Capital
  • Hikma Pharmaceuticals
  • Hikma Ventures
  • Huma
  • Human API
  • i2E
  • IA Ventures
  • Idinvest Partners
  • Imagia
  • IMINT Image Intelligence
  • imvaria
  • Indie Health
  • Innogest Capital
  • Invitalia Ventures
  • Iratel Ventures
  • Israel Innovation Authority
  • IXICO
  • Jana Care
  • Janssen Pharmaceuticals
  • JAZZ Venture Partners
  • Johnson & Johnson
  • Karate Health
  • Kinsa
  • Kleiner Perkins
  • Kontigo Care
  • Kryo
  • LaunchCapital
  • Lifeline Ventures
  • LifeOmic
  • LupusCorner
  • Lysol
  • MoodNetwork
  • Maxim Integrated Products
  • Mayo Clinic
  • Medidata Solutions
  • Medopad
  • MedScaler
  • Merck
  • Merck Ventures
  • Mindstrong Health
  • MIT Media Lab
  • MP Healthcare Venture Management
  • MSD Capital
  • Nanowear
  • NASCAR
  • National Health Service
  • National Institute of Allergy and Infectious Diseases
  • National Institute on Drug Abuse (NIDA)
  • National Institutes of Health (NIH)
  • National Basketball Association (NBA)
  • Neoteny 4
  • NeuraMetrix
  • Neurocast
  • NeuroLex Labs
  • Neurotrack
  • New Leaf Venture Partners
  • NEXT VENTŪRES
  • NGK Spark Plugs
  • NMC Health
  • NMC Lifesciences
  • Nordic Makers
  • Novartis
  • Novatio Ventures
  • N-Strategy Consulting Services
  • NWS Holdings
  • OCA Ventures
  • Ohio Innovation Fund
  • Oklahoma Medical Research Foundation
  • Olive Healthcare
  • Omidyar Technology Ventures
  • OpenView Venture Partners
  • Orikami
  • Oura
  • Pacific Health Ventures
  • Palisades Growth Capital
  • Pear Therapeutics
  • PeerWell
  • Pfizer
  • Philips
  • Plains Venture Partners
  • PM360
  • Polytech Ventures
  • Pritzker Group
  • Pritzker Group Venture Capital
  • Progentec Diagnostics
  • Propeller Health
  • Proxy Ventures
  • PureTech Health
  • Quanterix
  • RAE Health
  • RavenOye
  • Readout Health
  • ResApp Health
  • Rett Syndrome Research Trust
  • Revera
  • Roche
  • Romulus Capital
  • Sage Bionetworks
  • Salesforce Ventures
  • Sanofi
  • Science 37
  • Senza
  • Sesame Street
  • Shanghai Fosun Pharmaceutical
  • Silicon Valley Bank
  • SIME Diagnostics
  • Simul Investments
  • Singtel Innov8
  • Small Business Research Initiative (SBRI) Healthcare
  • Sonde Health
  • South Valley Angels
  • Spice Capital
  • Spirosure
  • SpringRock Ventures
  • Stanford University
  • Startup Basket
  • StartUp Health
  • State of Colorado
  • Sway Medical
  • Syneos Health
  • Takeda Pharmaceuticals
  • Tarilian Laser Technologies
  • TechniPlast
  • Teladoc Health
  • Temasek
  • National Center for Women & Information Technology (NCWIT)
  • Tribeca Venture Partners
  • Trustbridge
  • U-Care Medical
  • United States Air Force
  • University College London
  • University of California, San Francisco (UCSF)
  • University of Cincinnati
  • University of Witwatersrand
  • Vala Sciences
  • Venture Kick
  • Verily Life Sciences
  • Vignet
  • VI Partners
  • Vivante Health
  • Vivo India
  • Vivoryon Therapeutics
  • VivoSense
  • Vocalis Health
  • Vyaire Medical
  • Welsh Government
  • West Virginia University Rockefeller Neuroscience Institute
  • Winterlight Labs
  • Women’s National Basketball Association (WNBA)
  • YouGene
  • ZenStone Venture Capital
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll